This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

PROMINENT study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

PROMINENT study

  • randomized trial of pemafibrate for triglyceride reduction in the prevention of cardiovascular disease investigated the effect of pemafibrate on CV outcomes in patients with T2DM, TG 200-499 mg/dL and HDL <=40 mg/dL

  • total of 10,497 patients were randomized to pemafibrate 0.2 mg twice daily or placebo
    • primary endpoint was MI, ischemic stroke, coronary revascularization or CV death
    • median follow-up was 3.4 years

  • study results:
    • was no difference between groups for the primary endpoint of MI, ischemic stroke, coronary revascularization or CV death (HR 1.03, 95% CI 0.91-1.15, P=0.67). Total mortality was also similar in both groups (HR 1.04, 95% CI 0.91-1.20)

    • safety results showed an increased risk of venous thromboembolism (HR 2.05, 95% CI 1.35-3.17) and renal adverse events (HR 1.12, 95% CI 1.04-1.20) in the pemafibrate group

  • conclusion:
    • pemafibrate reduced TG, VLDL-c, remnant cholesterol and ApoCIII by 20 to 30% in patients with T2DM, mild-to-moderate hypertriglyceridemia and low HDL-c
    • pemafibrate did not reduce CV outcomes, compared with placebo in this population

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.